Vol.4 No.4 (December 2014)
Clinical Curative Effect Observation of the Treatment of Metastatic Breast Cancer (MBC) with Capecitabine Medicine or Combination Chemotherapy
李 杰 ：贵阳医学院，贵阳
Objective: To observe the clinical curative effect, toxic and side effect after the treatment of anth-racene ring and Paclitaxel chemotherapy with capecitabine for the recurrence metastasis of breast cancer. Method: From July 2007 to June 2014, Guizhou tumor hospital’s breast and gynecological oncology section received and treated 20 patients with metastatic breast cancer, among which, there were 4 cases with neck and supraclavicular lymph node metastasis, 5 cases with pulmonary metastasis, 4 cases with bone metastases, 1 case with liver metastasis, 1 case with brain metastases, 1 case with skin metastasis, 1 case with contralateral breast transfer and 3 cases with systemic multiple transfer. All patients underwent anthracycline or/and taxane adjuvant chemotherapy. They were given capecitabine medicine or combination chemotherapy. The median KPS score before the treatment in full cases was 90. there were 2 cases with capecitabine medicine; 2 cases with Capecitabine combined with Trastuzumab; 1 case with Capecitabine combined with bevacizumab; 9 cases with Capecitabine combined with gemcitabine; 1 case with Capecitabine combined with cis-platinum; 2 cases with Capecitabine combined with TAX (taxol); 3 cases with Capecitabine combined with docetaxel; 2 - 6 cycles of chemotherapy, the median cycles: 4. For all patients, the objective evaluation criteria in solid tumors (RECIST version 1.0) was used to evaluate the curative effect, and adverse reaction was evaluated by the toxicity of anticancer drug WHO standard evaluation. Result: There was 1 case lost to evaluate because of failure to follow-up. There were 19 cases evaluable, among which, 1 case reached CR; 6 cases reached PR; 6 cases reached SD; 6 cases reached PD, the effective rate of 36.8% (7/19). Transfer time is 2 - 33 months after treatment. The progression-free survival is 13 months. In 20 cases, 1 case had 4 degrees of bone marrow inhibition, 1 case had level 3 vomit gastrointestinal reaction, and they got better after symptomatic treatment; the remaining patients with 1 - 2 levels of digestive tract reaction could tolerate. There were 4 cases with 1 - 2 levels of extremities syndrome. Conclusion: The capecitabine multidrug therapy has certain curative effect on the metastatic breast cancer with failure of anthracene ring and Paclitaxel chemotherapy and the adverse reactions can be tolerated, so it is an effective treatment scheme.
李 杰 , 李凤虎 , 常建英 , 李杰慧 , 袁 佳 , 刘诗苑 , 冉 立 (2014) 卡培他滨单药或联合方案治疗转移性乳腺癌临床疗效观察。 临床医学进展， 4， 85-90. doi: 10.12677/ACM.2014.44016
 潘辉林, 黄岩, 宋慧胜, 等 (2009) 多西他赛联合卡培他滨治疗复发转移性乳腺癌临床观察. 实用癌症杂志, 6, 641-642.
 任洁 (2013) 多西紫杉醇联合卡培他滨治疗转移性乳腺癌的疗效分析. 实用癌症杂志, 6, 649-651.
 O’Shaughnessy, J., Miles, D., Vukelja, S., et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. Journal of Clinical Oncology, 20, 2812-2823.
 Karachaliou, N., Ziras, N., Syrigos, K., et al. (2012) A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 70, 169-176.
 Stockler, M.R., Harvey, V.J., Francis, P.A., et al. (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. Journal of Clinical Oncology, 29, 4498- 4504.
 肖华伍, 欧阳取长 (2012) 含卡培他滨方案治疗复发转移性乳腺癌的临床观察. 中国肿瘤临床与康复, 3, 221- 223.
 李剑英, 季从飞, 陈佳, 等 (2014) 卡培他滨维持治疗晚期乳腺癌的临床观察. 中国癌症杂志, 5, 381-385.
 王涛, 江泽飞, 宋三泰, 等 (2004) 单药希罗达治疗复发转移性乳腺癌的疗效观察. 中华肿瘤杂志, 6, 379-381.
 姜丽娜, 于世英, 熊慧英, 等 (2004) 胸苷磷酸化酶在癌组织中表达的研究. 中华肿瘤杂志, 5, 297-299.
 Zielinski, C., Gralow, J., Martin, M., et al. (2010) Optimising the dose of capecitabine in metastatic breast cancer: Confused, clarified or confirmed? Annals of Oncology, 21, 2145-2152.
 Tubiana-Mathieu, N., Bougnoux, P., Becquart, D., et al. (2009) All-oral combination of oral vinorelbine and capecitabine as first-line chemo-therapy in HER2-negative metastatic breast cancer: An International Phase II Trial. British Journal of Cancer, 101, 232-237.
 Martin, M., Makhson, A., Gligorov, J., et al. (2012) Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or meta static breast cancer. Oncologist, 17, 469-475.
 Tan, W.W., Allred, J.B., Salim, M., et al. (2012) Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: A north central cancer treatment group trial. Clinical Breast Cancer, 12, 81-86.
 黄红艳, 江泽飞, 王涛, 等 (2011) 卡培他滨单药或联合方案治疗晚期乳腺癌的疗效和安全性. 中华肿瘤杂志, 11, 850-853.
 农先胜, 黄显实 (2012) 卡培他滨单药或联合用药治疗复发/转移性乳腺癌的疗效观察. 中国癌症防止杂志, 4, 336-339.